Cargando…
Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas
Glioma, which accounts for more than 30% of primary central nervous system tumours, is characterised by symptoms such as headaches, epilepsy, and blurred vision. Glioblastoma multiforme is the most aggressive, malignant, and lethal brain tumour in adults. Even with progressive combination treatment...
Autores principales: | Zhang, Qing, Xiang, Wei, Yi, Dong-ye, Xue, Bing-zhou, Wen, Wan-wan, Abdelmaksoud, Ahmed, Xiong, Nan-xiang, Jiang, Xiao-bing, Zhao, Hong-yang, Fu, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109313/ https://www.ncbi.nlm.nih.gov/pubmed/30143053 http://dx.doi.org/10.1186/s13287-018-0977-z |
Ejemplares similares
-
CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression
por: Zhang, Qing, et al.
Publicado: (2018) -
CD90(low) glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells
por: Xue, Bing-zhou, et al.
Publicado: (2021) -
Correction to: CD90(low) glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells
por: Xue, Bing-zhou, et al.
Publicado: (2021) -
Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells
por: Zhang, Qing, et al.
Publicado: (2021) -
Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges
por: Lee, Myoung Woo, et al.
Publicado: (2019)